Novartis projects 5-6% sales growth through 2030 as peak sales outlook for Kisqali, Scemblix increases
Source: SeekingAlpha
2025-11-20 01:44:55 ET
More on Novartis
- Novartis AG (NVS) Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies Transcript
- Novartis AG (NVS) Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies - Slideshow
- Novartis AG (NVS) Q3 2025 Earnings Call Transcript
- Novartis to establish a manufacturing center in North Carolina
- Novartis says novel antimalarial succeeded in late-stage trial
Read the full article on Seeking Alpha
For further details see:
Novartis projects 5–6% sales growth through 2030 as peak sales outlook for Kisqali, Scemblix increases
Novartis AG
NASDAQ: NVS
NVS Trading
0.13% G/L:
$143.56 Last:
820,617 Volume:
$142.47 Open:
NVS Latest News
February 24, 2026 04:52:00 pm
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
NVS Stock Data
$303,205,301,793
1,889,070,162
N/A
868
N/A
Pharmaceuticals
Healthcare
CH
Basel
